CSL is a global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency and nephrology.

Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses: CSL Behring, CSL Seqirus and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 32,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest.

For inspiring stories about the promise of biotechnology, visit CSL.com/Vita and follow us on Twitter.com/CSL.

Masimo is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and consumer solutions.

Our mission is to improve patient outcomes, reduce the cost of care, and take noninvasive monitoring to new sites and applications.  Masimo’s breakthrough SET® pulse oximetry and rainbow® Pulse CO-Oximetry measurements allow accurate, reliable noninvasive and continuous monitoring in challenging conditions like motion and low perfusion, and of blood constituents that previously could only be measured invasively, like total hemoglobin (SpHb®).

Powered by the Masimo Hospital Automation™ platform, Masimo connectivity, automation, and telehealth solutions continue to improve and automate care delivery both in the hospital and the home.

From the Root® connectivity hub to home-based Masimo SafetyNet® for tetherless remote patient management and the newly announced W1™ watch, Masimo continues to advance the forefront of care.

Werfen is a growing, family-owned, innovative company founded in 1966 in Barcelona, Spain.

We are a worldwide leader in specialized diagnostics in the areas of Hemostasis, Acute Care Diagnostics, Transfusion, Autoimmunity, and Transplant. Through our Original Equipment Manufacturing (OEM) business line, we research, develop, and manufacture customized assays and biomaterials.

We operate directly in 30 countries, and in more than 100 territories through distributors. Our headquarters are in Barcelona, Spain and our Technology Centers are located in the United States and Europe. Worldwide sales exceeded $2.1 billion in 2023, and our workforce is more than 7,000 strong.

PharmaNutra S.p.A. was born with the aim of developing nutritional supplements and innovative medical devices, overseeing the whole production process, from the development of proprietary raw materials to the distribution of the finished product.

With its products distributed worldwide, in less than 20 years the company has succeeded in making its mark as a leading player in the iron-based oral nutritional supplements market, where it boasts major patents linked to Sucrosomial® Technology, a unique and innovative delivery system that has revolutionised the oral iron martial supplements sector, becoming one of the major market players thanks to the nutritional supplements in the SiderAL® line.

Founded in 2015 in Nantes (Upper Britany, France), i-SEP is a medtech specialized in intraoperative autotransfusion and Patient Blood Management. At i-SEP, we have developed, patented and now markets an innovative technology for the recovery and separation of blood components.

Together with our clinicians, we develop unique Patient Blood Management solutions for improved patient & stakeholder benefits.

We work closely with specialized clinicians with the aim of improving patient benefits, simplifying physicians’ workflow and helping reduce healthcare cost.

Our innovation brings significant added value compared to currently available solutions, particularly in terms of blood quality.

same™ is a new generation of intraoperative autotransfusion for haemorrhagic or high-risk surgery, able to recovering platelets and red blood cells.

HemoSonics International is revolutionizing point-of-care bleeding management by bringing you innovative solutions.

Quantra® Hemostasis Analyzer – a novel, closed-cartridge viscoelastic assay based on an innovative ultrasound technology. When time is critical, the Quantra System offers rapid, precise, and easy to interpret coagulation results that enable clinicians to make quick and informed treatment decisions. Because of its simple, intuitive, and safe POC workflow from sample collection to result, the Quantra System is ideally suited for point-of-care use.

qLabs FIB measures Fibrinogen levels within 1 to 5 minutes. From a single drop of blood, qLabs FIB delivers robust, lab comparable results, with integrated hematocrit adjustment, helping clinicians to give the right product at the right moment to manage post-partum hemorrhage.

HemoSonics International is a Stago Group company. Stago is a major player in the IVD industry and a recognized leader in the field of hemostasis and thrombosis for over 50 years. Stago has a distribution network of subsidiaries and distributors in more than 110 countries. For more information, visit: www.hemosonics.com and www.stago.com

LFB is a biopharmaceutical group that develops, manufactures, and markets plasma-derived medicinal products and recombinant proteins for the treatment of patients with serious and often rare diseases.

Created in France in 1994, LFB today is a leading European company providing plasma-derived medicinal products to healthcare professionals. Its mission is to offer patients new
treatment options for unmet needs in three major therapeutic areas: immunology, haemostasis and intensive care.

LFB’s current market porƞolio includes 15 biomedicinal products sold in about 30 countries.

For more information about LFB, go to: www.groupe-lfb.com

Advancis Surgical is delighted to release the next generation of Hemosep – our innovative cell salvage system.

The Hemosep cell salvage system is designed to recover blood loss during cardiac and other surgical specialities, providing a concentration of all cell species for transfusion back to the patient.

Hemosep is an easy to use system, maintaining platelet function and clotting factors, in a gentle hemonconcentrating filtration system. Not only can Hemosep be used to filter and concentrate the residual blood following the termination of the CPB system, having its own intra-operative reservoir, means that Hemosep can also be utilised in other medium to heavy bleed surgeries such as orthopaedics, gynaecology, spinal, transplant and vascular surgery.

It offers exciting new opportunities for health services to improve patient outcomes, reduce the risk of contamination and reaction and reduce the cost of autologous blood transfusion.

Brightwake brings together the knowledge from its brand portfolio (Advancis Surgical and Advancis Medical) to create an end-to-end design & development company, specialising in medical device manufacturing. Based in Nottingham in the United Kingdom, our talented team of researchers, designers and engineers are responsible for some of the world’s leading innovations today.

Founded in 1979, Brightwake’s strength is driven through our no-nonsense approach to product development and problem solving through our highly skilled engineering department and portfolio of brands.

In 2004 we launched Advancis Medical, which is now one of the leading international medical wound care companies, focusing on marketing the developments Brightwake has inspired.

The Advancis Surgical team would be delighted to demonstrate our innovative system to you today at NATA and discover how you can gain access to the live demonstrations via our European distributor partners.

We are a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services.

Backed by over five decades of industry expertise, our blood management technologies are designed to drive procedural effectiveness and elevate the patient experience. We deliver quality hospital solutions that prioritise patient outcomes, so that clinicians can confidently provide the best possible care.

To learn more, please visit: www.haemonetics.com

Pharmacosmos A/S is a global leader in carbohydrate chemistry and innovative treatments for iron deficiency and iron deficiency anaemia. Building on our foundational expertise in carbohydrate chemistry and cell cycle biology, we develop innovative treatments for unmet patient needs, with a focus on iron metabolism and blood-related disorders. Founded in 1965 and headquartered in Denmark, our team is made up of more than 700 specialists across the UK, Ireland, the Nordics, Germany, the USA, and China.

As the market leader in haematology diagnostics, we support healthcare professionals around the world providing a broad range of medical diagnostics products and solutions. Our multi-functional solutions work together with high-quality reagents and reliable service and support to create a better healthcare journey for all. Our haematology solutions facilitate clinical interpretation of laboratory data of blood and bone marrow specimens. They also allow for clinical and research parameters, adding greater clinical value. 

Sysmex Europe SE, located near Hamburg, Germany, is a subsidiary of the Sysmex Corporation from Kobe, Japan. From our Hamburg offices, we serve our affiliates, distributors and customers throughout Europe, the Middle East, and Africa (EMEA).

For more information, visit www.sysmex-europe.com.

Lindis Blood Care is setting new standards for blood management during cancer surgeries with CATUVAB® – the first medical device designed to reliably remove tumor cells from intraoperative blood.

Using a bispecific antibody to induce formation of aggregates between tumor and immune cells, CATUVAB® enables their physical removal through filtration within standard IBS procedures that can be seamlessly integrated into clinical practice. By making autologous blood transfusions accessible for more patients, CATUVAB® reduces reliance on donor blood, which carries risks such as allergic reactions and immune suppression.

It also provides a tailored solution for individuals unable to receive donor blood while helping to ease global blood shortages. With CE certification imminent, Lindis is looking forward to launching in Germany and Austria in 2025, marking a new era of Patient Blood Management in cancer surgery.

Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines.

Octapharma employs more than 11,000 people worldwide to support the treatment of patients in 120 countries with products across three therapeutic areas: Immunotherapy, Haematology and Critical Care.

Octapharma has seven R&D sites and five state-of-the-art manufacturing facilities in Austria, France, Germany and Sweden, and operates more than 195 plasma donation centres across Europe and the US.